跳至主要内容
临床试验/NCT03436771
NCT03436771终止不适用

Long-Term Follow-up Protocol for Subjects Treated With a CAR T-Cell Product on a Juno-Sponsored Clinical Trial

Juno Therapeutics, a Subsidiary of Celgene2 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2018年2月19日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
4
试验地点
2
主要终点
Proportion of patients with detectable viral vector sequences

研究概览

简要总结

This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients who have received at least one dose of a Juno CAR T-cell product (listed above) in a Juno-sponsored clinical trial
  • Patients who have provided informed consent for the long-term follow-up study

排除标准

  • None. All patients who have previously received treatment with a Juno CAR T-cell product are eligible for this long-term follow-up study.

结局指标

主要结局

Proportion of patients with detectable viral vector sequences

时间窗: 15 years from last treatment

Proportion of patients with detectable RCR or RCL

时间窗: 15 years from last treatment

Proportion of patients with adverse events

时间窗: 15 years from last treatment

次要结局

  • Overall survival(15 years from last treatment)
  • Progression-free survival(15 years from last treatment)

研究者

发起方
Juno Therapeutics, a Subsidiary of Celgene
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验